source
- Novo Nordisk reports board and executive share transactions under EU market abuse rulesOn August 6, 2026 Novo Nordisk issued a company announcement detailing share transactions made by members of its board, senior executives and their close associates in line with Article 19 of EU Re…
- Context Therapeutics drops CT-95 bispecific T-cell engager to stretch cash runway to 2027Context Therapeutics announced it is halting development of its bispecific T-cell engager CT-95. The company acquired CT-95 in 2024 for $3.7 million and began dosing patients in a phase 1 trial in…